期刊文献+

硫酸沙丁胺醇脉冲释药微丸的制备及其体外释药研究 被引量:2

Preparation of Salbutamol Sulfate Pulsatile Release Pellet and study on its release in vitro
下载PDF
导出
摘要 目的研究硫酸沙丁胺醇脉冲释药微丸的制备方法及其体外释放。方法用空白丸芯依次进行含药层(SBA),溶胀层(低取代羟丙纤维素)及控释层(乙基纤维素水分散体)包衣制备硫酸沙丁胺醇脉冲释药微丸。采用紫外法和蓝法考察含药层、溶胀层及控释层在生理盐水中药的体外释放。结果含药层在生理盐水中能正常释药,溶胀层和控释层的增重对脉冲释药微丸的释药时滞和释药速率均有明显影响,溶胀层包衣增重15%,控释层包衣增重20%所制成释药微丸,释药时滞时间约为4.1 h时,这正好对应哮喘患者清晨2∶00发作时晨。结论所制备的硫酸沙丁胺醇脉冲释药微丸具有体外脉冲释药特性,适合哮喘患者预防用药。 Objective To investigate the preparing method of Salbutamol Sulfate Pulsatile Release Pellets and its release in vitro. Methods Salbutamol Sulfate Pulsatile Release Pellets were prepared by using black core coated with Salbutamol Sulfate as drug containing layer (SBA), swelling agent layer (L-HPC) and controlled-release layer (ethylcellulose aqueous dispersion). The release properties in vitro of drug containing layer, swelling agent layer and controlled-release layer were studied by using UV method and basket method. Results Drug containing layer could release active ingredients normally into normal saline. The increased weight of swelling agent layer and controlled-release layer had obviously influences on lag time and velocity of drug release. Weights of swelling agent layer and controlled release layer were increased by 15% and 20%, respectively. The lag time was about 4.1 h for the prepared drug release pellets, matching with the fact that asthma usually attacked at 2:00 in the morning. Conclusion The prepared Salbutamol Sulfate Pulsatile Release Pellet can release drugs in vitro in pulsatile style, and it is appropriate to be used as preventive drugs for asthma patients.
出处 《中国医药导报》 CAS 2013年第19期124-126,共3页 China Medical Herald
关键词 硫酸沙丁胺醇 脉冲释药微丸 研制 体外释放 Salbutamol Sulfate Pulsatile Release Pellets Development Release in vitro
  • 相关文献

参考文献15

二级参考文献74

共引文献42

同被引文献25

  • 1冯年平,屠锡德.盐酸拉贝洛尔缓释片及其药动学研究[J].中国药科大学学报,1996,27(1):13-15. 被引量:5
  • 2Zhang Yong, Huo MeiRong, Zhou JianPing, et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles[J].AAPS J,2010,12(3):263-271.
  • 3Zhang Yong,Huo MeiRong,Zhou JianPing,et al. PKSolver:an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel[J].Comput Methods Programs Biomed,2010,99(3):306-314.
  • 4Dashevsky A, Mohamad A. Development of pulsatile muhiplarticulate drug delivery system coated with aqueous dispersion Aquacoat (R) ECD [J]. International journal of pharmaceutics, 2006,318 (1-2) : 124-131.
  • 5Jagdale SC, Chede SM, Gulwady R,et al. Pulsatile Multiparticulate Drug Delivery System for Metoprolol Succinate. Archives of Pharmacal Research [J]. 2011,34(3):369-376.
  • 6Hung SF, Hsieh CM, Chen YC, et al. Formulation and process optimization of muhiparticulate pulsatile system delivered by osmotic pressure-activated rupturable membrane [J]. International journal of pharmaceutics, 2015,480(1-2) : 15-26.
  • 7Chaudhary SS,Patel HK,Parejiya PB,et aL Chronomodulated drug delivery system of urapidil for the treatment of hypertension[J]. Int J Pharm Investig,2015,5 (2) : 107- 113.
  • 8Yadav D, Survase S,Kumar N. Dual coating of swellable and rupturable polymers on Glipizide loaded MCC pellets for pulsatile delivery: Formulation design and in vitro evaluation [J]. International Journal of Pharmaceutics, 2011,419(1-2) : 121-130.
  • 9Sungthongjeen S,Puttipipatkhachorn S,Paeratakul O,et al. Development of pulsatile release tablets with swelling and rupturable layers [J]. Journal of controlled release, 2004,95(2) : 147-159.
  • 10Bussemer T, Bodmeier R. Formulation parameters affecting the performance of coated gelatin capsules with pulsatile release profiles [J]. International Journal of Pharmaceutics, 2003,267(1-2) : 59-68.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部